陳怡榮副研究員

陳怡榮 副研究員
分子與基因醫學研究所
連絡電話:886-37-206166-35311
E-mail:yrchen@nhri.edu.tw

 

 

 

學歷

Ph.D., Institute of Microbiology and Immunology, Baylor College of Medicine (1998), Lab of Dr. Tse-Hua Tan; Apoptotic signaling mediated by c-Jun N-terminal kinase
M.S., Institute of Microbiology and Immunology, National Yang-Ming Medical College (1991), Lab. of Dr. Sheng-Yuan Wang; purification and characterization of a bone marrow-derived hematopoietic colony-promoting activity
B.S., Department of Medical Technology, National Taiwan University (1989)

經歷

2008 – present

Associate Investigator, Institute of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan, R.O.C.

2003 – 2008

Assistant Investigator, Division of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan, R.O.C.

2002 – 2003

Assistant Professor, Department of Immunology, Baylor College of Medicine, Houston, Texas

1998 – 2002

Postdoctoral Associate, Department of Immunology, Baylor College of Medicine, Houston, Texas

1993 – 1994

Research Assistant, Institute of Biomedical Science, Academia Sinica, Taiwan

1990 – 1991

Research Assistant, Veterans General Hospital, Taipei, Taiwan, R.O.C.

1988 – 1989

Training student, Institute of Biomedical Science, Academia Sinica, Taiwan, R.O.C.

研究興趣

磷酸化是細胞中最重要的蛋白質修飾機制之一。蛋白質磷酸化的程度則由激酶與磷酸酶的平衡作用來決定。相較於對蛋白質激酶的了解,投注於蛋白質磷酸酶之研究相對少得很多。人類基因序列的解讀大幅減輕了尋找新磷酸酶的困難。在人類基因體中存在一群有趣的蛋白質磷酸酶─雙特異性磷酸酶。雙特異性磷酸酶的歸類起源於它們都有類似MAPK (mitogen-activated protein kinase)磷酸酶之構造,而MAPK磷酸酶可以同時去除 MAPK 中色胺酸、酥胺酸與酪胺酸之磷酸化。目前依其序列之相似度,有六十一個磷酸酶被歸類成雙特異性磷酸酶。其中有十九個是「非典型雙特異性磷酸酶」。非典型雙特異性磷酸酶有類似MAPK磷酸酶之活性部位,但沒有或具有很低的MAPK磷酸酶活性。釐清非典型雙特異性磷酸酶的功能是一熱門研究課題。

非小細胞肺癌是國人癌症致死的首因之一。上皮細胞生長因子受體突變則是國人非小細胞肺癌最常出現之變異。上皮細胞生長因子受體牽涉於許多重要之細胞功能如細胞繁殖、分化、移動、和存活。我們的研究專注於非典型雙特異性磷酸酶─VHR (vaccinia-H1 related)對上皮細胞生長因子受體訊息傳導之影響。同時對非典型雙特異性磷酸酶22與23在非小細胞肺癌致病機制之研究。此研究將提供磷酸酶如何調節酪胺酸激酶受體訊息傳導與細胞癌化機制之重要資訊。

榮譽與獲獎

2013

The 10th National Innovation Award (Pre-clinical and clinical development of DBPR112, a novel EGFR tyrosine kinase inhibitor as a therapeutic candidate for lung adenocarcinoma)

2000

Travel Award – Keystone Symposium, NIH Grant #1 R13 CA85280-01

1999 – 2002

Postdoctoral fellowship, Prostate Cancer Research Program, Department of Defense, USA

1998

Alexander Wang Memorial Scholarship, 1998 SCBA-Texas Chapter Symposium

1997

Travel Award – Keystone Symposium; NIH

1997

Platform presentation award, Graduate Student Symposium, Baylor College of Medicine, Houston

1997 – 1998

Deans Award (Graduate School, Baylor College of Medicine)

1997 – 1999

Predoctoral fellowship, Breast Cancer Research Program, Department of Defense, USA

1990 – 1991

Outstanding Student Scholarship, National Yang-Ming Medical College, Taiwan

1986 – 1989

Book Coupon Awards, National Taiwan University, Taiwan

學術著作

  1. Chou HC, Cheng CM, Yang CH, Lin TY, Liu YW, Tan TH, Chen YR*. DUSP3 regulates phosphorylation-mediated degradation of occludin and is required for maintaining epithelial tight junction. J. Biomed. Sci.,29: 40, 2022
  2. Lin TY, Yang CH, Chou HC, Cheng CM, Liu YW, Wang JY, Huang LR, Tsai SF, Huang SF, Chen YR*. EGFR mutation-harboring lung cancer cells produce CLEC11A with endothelial trophic and tumor-promoting activities. Cancers, 14: 1356, 2022
  3. Chen YR*, Chou HC, Yang CH, Chen HY, Liu YW, Lin TY, Yeh CL, Chao WT, Tsou HH, Chuang HC, Tan TH*. Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration. Oncogene, 36:6509-6517, 2017
  4. Yang CH, Yeh YJ, Wang JY, Liu YW, Chen YL, Cheng HW, Cheng CM, Chuang YJ, Yuh CH, Chen YR*. NEAP/DUSP26 suppresses receptor tyrosine kinases and regulates neuronal development in zebrafish. Sci. Reports, 7: 5241, 2017
  5. Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, Liu KJ, Chang GC, Tsai TF, Tsai SF, Liu HP, Wu YC, Chen YT, Huang SF*, Chen YR*. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. BBA-Mol. Basis Dis., 1852: 1540–1549, 2015
  6. Wang JY, Yeh CL, Chou HC, Yang CH, Fu YN, Chen YT, Cheng HW, Huang CY, Liu HP, Huang SF, Chen YR*. Vaccinia H1-related phosphatase (VHR) is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer. J Biol. Chem. 286:10177-10184, 2011
  7. Li JP, Fu YN, Chen YR*, and Tan TH*.JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J. Biol. Chem. 285: 5472-5478, 2010
  8. Wang JY, Yang CH, Yeh CL, Lin CH, Chen YR*. Neuroendocrine-associated phosphatase (NEAP) causes down-regulation of epidermal growth factor receptor, subsequently induces the suppression of nerve growth factor-induced differentiation in PC12 cells. J. Neurochem. 107: 1544-1555, 2008
  9. Fu YN, Yeh CL, Cheng HH, Yang CH, Tsai SF, Huang SF, Chen YR*. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene, 27: 957-965, 2008
  10. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF*. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene, 25: 1205-1215, 2006

專利

  1. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物. TWI385174, Feb. 11, 2013
  2. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors. US8507502B2, Aug. 13, 2013
  3. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物. CN102264745B, July 22, 2015
  4. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors. JP5781934, July 24, 2015-
  5. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors. KR101703941B1, Feb. 7, 2017
  6. Hsieh, HP; Coumar, MS; Hsu, TA; Lin, WH; Chen, YR; Chao, YS. Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors. PCT/US2009/063684 (WO 2010/054285 A3)

 

實驗室成員

 

Comments are closed.